Premium
Captopril, a specific inhibitor of angiotensin converting enzyme, enhances both trypsin and vitellogenin titers in the grey fleshfly Neobellieria bullata
Author(s) -
Vandingenen A.,
Hens K.,
Macours N.,
Zhu W.,
Janssen I.,
Breuer M.,
De Loof A.,
Huybrechts R.
Publication year - 2001
Publication title -
archives of insect biochemistry and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.576
H-Index - 66
eISSN - 1520-6327
pISSN - 0739-4462
DOI - 10.1002/arch.1047
Subject(s) - captopril , vitellogenin , hemolymph , biology , endocrinology , medicine , angiotensin converting enzyme , yolk , midgut , biochemistry , botany , ecology , blood pressure , gene , larva
A strong and constitutive angiotensin converting enzyme‐ or ACE‐like activity was demonstrated in the hemolymph of the adult grey fleshfly Neobellieria bullata . In a competition assay, the N. bullata trypsin modulating oostatic factor ( Neb ‐TMOF) was confirmed to be an in vitro substrate for this circulating Neb ‐ACE. Oral uptake of captopril, a selective and specific inhibitor of ACE, resulted in a complete phenotypic knockout of circulating ACE activity. When compared with control animals, captopril‐fed female flies showed an increase in the liver meal–induced trypsin peak in the midgut and elevated levels of protein meal–induced yolk polypeptides in the hemolymph. The latter effect was not due to a slower vitellogenin uptake by the ovaries, because oocyte growth was not affected by the captopril treatment. The apparent synergism between the demonstrated ACE functionality and the previously reported effects of the oostatic peptide Neb ‐TMOF are discussed in the context of our recent finding that Neb ‐TMOF represents a prime candidate for being the first known in vivo substrate for circulating insect ACE. Arch. Insect Biochem. Physiol. 47:161–167, 2001. © 2001 Wiley‐Liss, Inc.